1.49
Schlusskurs vom Vortag:
$1.41
Offen:
$1.4
24-Stunden-Volumen:
60,204
Relative Volume:
1.48
Marktkapitalisierung:
$5.44M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-4.53M
KGV:
-1.2024
EPS:
-1.2392
Netto-Cashflow:
$-4.69M
1W Leistung:
+7.97%
1M Leistung:
+19.20%
6M Leistung:
-63.66%
1J Leistung:
-82.87%
Pulmatrix Inc Stock (PULM) Company Profile
Firmenname
Pulmatrix Inc
Sektor
Branche
Telefon
(888) 355-4440
Adresse
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PULM
Pulmatrix Inc
|
1.49 | 5.15M | 3,000 | -4.53M | -4.69M | -1.2392 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-09 | Eingeleitet | H.C. Wainwright | Buy |
Pulmatrix Inc Aktie (PULM) Neueste Nachrichten
PULM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulmatrix Q2 2025 Earnings: Loss Per Share of $0.42 as Clinical Pipeline AdvancesEarnings Preview - newsline.com
Pulmatrix Q2 2025 Earnings: Net Loss of $0.42 per Share as Biotech Continues Pipeline DevelopmentReturn On Capital - newsline.com
PULM Q2 2025 Earnings: Clinical-Stage Biotech Reports EPS of -$0.42Revenue Inflection Point - newsline.com
Pulmatrix Inc. (PULM) Q2 2025 Earnings: Narrowing Losses Amid Clinical MilestonesCore Business Growth - newsline.com
Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track - Stock Titan
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum - GlobeNewswire Inc.
Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends - Stock Titan
Pulmatrix Stock Slides As Eos Merger Clock Starts To Matter For PULM Holders - Bez Kabli
PULM Q2 2025 Earnings: Reported Loss of $0.42 per Share as Company Advances PipelineEarnings Weakness Phase - newsline.com
PULM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmatrix (PULM) Gains 1.47% as Shares Approach Key Resistance LevelIntraday Trade Ideas - The Legal Advocate
Pulmatrix Inc. (PULM) Edges Higher as Stock Gains 3.68% – Key Levels in FocusProfitability Factor - The Legal Advocate
Pulmatrix Inc. (PULM) Holds Steady at $1.34 as Key Support and Resistance Levels TightenIsland Reversal - The Legal Advocate
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87% - The Legal Advocate
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
Pulmatrix Announces First Quarter 2026 Financial Results - Fidelity
TradingKey - TradingKey
Number of shareholders of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
The hidden strength in Pulmatrix (PULM) most investors miss (Volatility Increases) 2026-05-08Attention Stocks - newser.com
The hidden strength in Pulmatrix (PULM) most investors miss (Risk Aversion) 2026-05-08Crowd Entry Points - newser.com
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - Quantisnow
Pulmatrix (PULM) Stock: Is It Losing Market Strength |Shared Buy Zones - Newser
Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger - Stock Titan
PULM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmatrix, Inc. announced that it has received $1 million in funding - marketscreener.com
Pulmatrix closes $1M preferred stock placement with Eos affiliate - Investing.com
Pulmatrix Closes $1M Series B Preferred Stock Investment at $2.20 per Share as Part of Planned Merger with Eos SENOLYTIX 1 - Minichart
Pulmatrix announces closing of preferred stock transaction as part of planned merger - marketscreener.com
Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger - TradingView
Pulmatrix closes $1M preferred stock placement with Eos affiliate By Investing.com - Investing.com Canada
Pulmatrix Raises $1M in Preferred Stock Financing - TipRanks
Pulmatrix closes $1M Series B preferred private placement tied to planned merger - TradingView
Pulmatrix (NASDAQ: PULM) closes $1M Series B preferred tied to Eos merger - Stock Titan
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - PR Newswire
Pulmatrix (PULM) Stock: Why Working Capital (Trades Higher) 2026-04-20Fibonacci Analysis - Cổng thông tin điện tử tỉnh Lào Cai
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Momentum Shift: Is Pulmatrix Inc in a consolidation phase2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan
Finanzdaten der Pulmatrix Inc-Aktie (PULM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):